Study of serum interaction with a cationic nanoparticle: Implications for in vitro endocytosis, cytotoxicity and genotoxicity.
about
Genotoxicity of metal oxide nanomaterials: review of recent data and discussion of possible mechanisms.Anticancer drug-incorporated layered double hydroxide nanohybrids and their enhanced anticancer therapeutic efficacy in combination cancer treatmentPhysicochemical properties of surface charge-modified ZnO nanoparticles with different particle sizes.Biocompatibility, endocytosis, and intracellular trafficking of mesoporous silica and polystyrene nanoparticles in ovarian cancer cells: effects of size and surface charge groups.Drug release kinetics, cell uptake, and tumor toxicity of hybrid VVVVVVKK peptide-assembled polylactide nanoparticles.Biosafety and bioapplication of nanomaterials by designing protein-nanoparticle interactions.Mechanisms of genotoxicity. A review of in vitro and in vivo studies with engineered nanoparticles.Can the comet assay be used reliably to detect nanoparticle-induced genotoxicity?Carboxylated nanodiamonds can be used as negative reference in in vitro nanogenotoxicity studies.Influence of the surface charge of PLGA nanoparticles on their in vitro genotoxicity, cytotoxicity, ROS production and endocytosis.Titanium dioxide nanoparticles: an in vitro study of DNA binding, chromosome aberration assay, and comet assay.Peptide-biphenyl hybrid-capped AuNPs: stability and biocompatibility under cell culture conditions.Cellular entry of nanoparticles via serum sensitive clathrin-mediated endocytosis, and plasma membrane permeabilization.Mechanisms allowing protein delivery in nasal mucosa using NPL nanoparticles.Genotoxicity evaluation of asymmetric lipid polymer hybrid nanoparticles of doxycycline hydrochloride following intravenous administration.Comet assay reveals no genotoxicity risk of cationic solid lipid nanoparticles.Monitoring characteristics and genotoxic effects of engineered nanoparticle-protein corona.Positive charge, negative effect: the impact of cationic nanoparticles in the brain.Anticancer activity of ferulic acid-inorganic nanohybrids synthesized via two different hybridization routes, reconstruction and exfoliation-reassembly.
P2860
Q30884127-6B5E4FA3-83AB-4820-A368-B5B693F4E16BQ33593987-112DC557-084B-4BFD-8A08-2A8BD5E50A53Q34788316-7185D507-A947-4818-AFA5-727374970288Q36161045-C8802CB6-6FDE-4DDC-A8C3-F227EEA078DFQ36767228-D8AD9643-F640-46C8-B7DF-66E5968B1032Q38076084-9E0B48EA-CAAC-439C-A272-DE0FFDC49CBAQ38078983-0CA77382-A9DB-45AE-965B-41568605F6C8Q38285584-CFDF4F4D-6C7F-4BAA-ACAB-49DD20C7F824Q38717799-1899C54B-75AD-4593-9DF5-7F027EF8D4D4Q38826277-32174BED-57C2-473F-AC9D-1F2B16A5350CQ39041747-7470759A-4F4A-47A8-A272-AFDD6D8C690AQ39129852-125175DA-5C2D-4E8A-A100-2050ADCE497CQ39343797-32F56AD1-14A1-4CA3-8816-4D1CA62E6F32Q40713612-FFE574A9-B5F3-4512-A80F-53E9DCF213C3Q41195486-F467D1FC-FDFA-4BE2-B4B5-8981B4CFE029Q45787137-500E2C41-386F-4CBD-A719-73FDDF62E535Q46280545-130E1F88-DD3C-451B-B229-5E617524A6D9Q48516123-11AE6EA1-B43A-4663-83E9-4F788C0E0E58Q53634599-D5401581-C64C-4FCA-A730-11CBD28B77A8
P2860
Study of serum interaction with a cationic nanoparticle: Implications for in vitro endocytosis, cytotoxicity and genotoxicity.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Study of serum interaction wit ...... cytotoxicity and genotoxicity.
@en
Study of serum interaction wit ...... cytotoxicity and genotoxicity.
@nl
type
label
Study of serum interaction wit ...... cytotoxicity and genotoxicity.
@en
Study of serum interaction wit ...... cytotoxicity and genotoxicity.
@nl
prefLabel
Study of serum interaction wit ...... cytotoxicity and genotoxicity.
@en
Study of serum interaction wit ...... cytotoxicity and genotoxicity.
@nl
P2093
P1476
Study of serum interaction wit ...... cytotoxicity and genotoxicity.
@en
P2093
Alizée Brient
Anne Platel
Christophe Youta Dombu
Daniel Marzin
Fabrice Nesslany
Frank Le Curieux
Jiang Chang
Maysaloun Merhi
P356
10.1016/J.IJPHARM.2011.07.014
P407
P577
2011-07-27T00:00:00Z